

MAXGXIL[®]

Results

2008 A4M Conference

(American Academy of Anti-Aging Medicine Conference)


maxINTERNATIONAL[®]

PATENT PENDING ORAL GSH OPTIMIZER STUDY

Demographics

- 25 subjects evaluated
- Age range: 30-75 years old
- 14 females and 11 males
- No immunosuppressive drugs, active cancer, IDDM, autoimmune diseases
- No blood thinners

PATENT PENDING ORAL GSH OPTIMIZER STUDY

Study Schematic



- IRB approved, placebo-controlled, double-blind, crossover design
- 2 months on each arm of study
- 2 week washout between crossover
- Lab evaluation, screening, baseline, monthly and post crossover
- SF 32 QOL survey on same schedule as lab evaluation

Improvement in Lymphocyte Glutathione* Levels using a Patent Pending Oral Glutathione Optimizer





* Improvements in nanomolar range
3 Subjects with chronic insomnia
showed least improvement

Improvement in Age-Associated Hormone Levels using a Patent Pending Oral Glutathione Optimizer



Improvement in Age-Associated Hormone Levels using a Patent Pending Oral Glutathione Optimizer



*19/25 Subjects demonstrated improved TNFa
 **TNFa assay sensitive to 6 ng/mL
 ***6/25 Subjects demonstrated improved CRP levels

IMPROVEMENT IN QOL (SF32) WITH PATENT PENDING ORAL GSH OPTIMIZER

- Improved energy
- Increase in quality of sleep
- Improved mood
- Improved mental focus
- Decreased aches & discomfort

SUMMARY

- Patent pending oral GSH optimizer significantly raises lymphocyte GSH levels
- Increasing lymphocyte glutathione* is associated with improved levels of age-related hormones and markers of inflammation
- Similar although nonstatistical improvements observed in fasting glucose, insulin and lipid profiles
- Increased GSH associated with improvements in Quality of Life parameters
- All improvements increase sequentially over duration of study (mo. 2 > mo.1)

* Proprietary testing modality